This site is intended for healthcare professionals

GenSight Biologics announces publication analyzing visual parameters of ND4-LHON subjects.

Read time: 2 mins
Last updated:10th Sep 2021
Published:10th Sep 2021
GenSight Biologics announced that the Journal of Neuro-Ophthalmology has published a paper on a cross-sectional analysis of the baseline (pre-treatment) characteristics of the ND4-LHON subjects enrolled in the RESCUE and REVERSE Phase III trials of Lumevoq.
Condition: Leber's Hereditary Optic Neuropathy
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest